Institutional net value change of -$11.2B and net sellers outpacing buyers 957 to 855 confirm active distribution. No insider filings to counter the selling pressure.

Confirmation

Continued net selling in the next 13F quarter or new insider sales filings would reinforce this bearish stance.

Invalidation Risk

A sudden reversal to institutional accumulation or a surge in insider buying would invalidate the bearish view.

These game-theory scenarios are AI-generated from public 13F data and reflect historical patterns only — not a trading recommendation.

Insider Trading (Form 4)

12-Month Buy/Sell Activity

Jan 25

May 25

BuySell

Action	Insider	Title	Date	Value
Sell	Finucane Anne A.	Director	2025-08-20	$533K
Buy	SANSONE GUY P	Director	2025-06-05	$100K
Sell	ROBBINS LARRY	Director	2025-05-06	$10.00M
Sell	ROBBINS LARRY	Director	2025-05-05	$6.59M
Sell	ROBBINS LARRY	Director	2025-05-05	$82.66M
Sell	ROBBINS LARRY	Director	2025-05-02	$15.22M
Sell	ROBBINS LARRY	Director	2025-05-02	$113.20M
Sell	ROBBINS LARRY	Director	2025-05-02	$26.04M

View all insider trades →

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding CVS HEALTH CORP (CVS)?

Major stakeholders currently include BlackRock, Inc. ($9.0B), Vanguard Capital Management LLC ($5.9B), Capital World Investors ($5.5B). Based on the latest 13F filings, there are a total of 1878 tracked investment funds and institutions maintaining positions in CVS.

What is the overall institutional sentiment toward CVS recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $11.2B, driven by 855 managers accumulating shares while 957 reduced their exposure.

Which institutions have been selling or reducing their CVS positions?

In the latest period, 759 funds trimmed their holdings, and 198 managers completely exited their positions. The aggregate reported sell value was $45.1B.

Are there any notable investors adding CVS to their portfolios?

Yes, buying activity remains notable. 129 institutions opened new positions in {ticker}, and 726 existing holders added to their shares. The total reported buy value for the quarter amounted to $39.7B.